Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Karl Schorno"'
Autor:
Amanda E. Brinker, Tammy Ham, Gregory A. Reed, Kathy Heppert, Lian G. Rajewski, John A. Taylor, William McCulloch, Roy A. Jensen, Karl Schorno, Shrikant Anant, Michael Dalton, Scott Weir, Michael Baltezor, Robyn Wood, Prabhu Ramamoorthy, Michael J. McKenna, Mehmet Tanol
Publikováno v:
J Pharmacol Exp Ther
Brinker, Amanda/0000-0003-1134-0572; Weir, Scott/0000-0002-8020-434X WOS:000477702600002 PubMed: 31113837 Pharmacokinetic studies in rats and dogs were performed to characterize the in vivo performance of a novel prodrug, fosciclopirox. Ciclopirox ol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3926e20ca9e59b65eab474660a87062a
https://doi.org/10.1124/jpet.119.257972
https://doi.org/10.1124/jpet.119.257972
Autor:
Prabhu Ramamoorthy, Scott Weir, Greg Reed, Tammy Ham, Manish R. Patel, Michael Dalton, William McCulloch, Amanda E. Brinker, Karl Schorno, Valentina Zhukova-Harrill, Howard A. Burris, Gerald Steven Falchook, Shrikant Anant, Paul Chester Toren, Roy A. Jensen, John A. Taylor, Michael Baltezor, Susanna Varkey Ulahannan, Robyn Wood
Publikováno v:
Journal of Clinical Oncology. 37:e14705-e14705
e14705 Background: Ciclopirox Prodrug (CPX-POM) is a novel anticancer agent currently being evaluated in patients with advanced solid tumors participating in a First-in-Human, Phase 1 safety, dose tolerance, pharmacokinetics (PK) and pharmacodynamics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bebedc0449a381c6777cc6150e079f71
https://doi.org/10.1200/jco.2019.37.15_suppl.e14705
https://doi.org/10.1200/jco.2019.37.15_suppl.e14705
Autor:
Scott Weir, Michael Baltezor, Roy A. Jensen, Robyn Wood, Michael J. McKenna, Greg Reed, John A. Taylor, Shrikant Anant, Partha Ranjarajan, Prabhu Ramamoorthy, Karl Schorno, Lian Rajweski, William McCulloch, Kathy Heppert, Amanda E. Brinker
Publikováno v:
Cancer Research. 78:5882-5882
Ciclopirox (CPX) is contained in a number of FDA-approved topical antifungal drug products as the free acid and olamine salt. CPX possesses anticancer activity in a number of in vitro and in vivo preclinical models. Its clinical utility is limited as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f040e4b2028d879dca3fe0a4636e6ac5
https://doi.org/10.1158/1538-7445.am2018-5882
https://doi.org/10.1158/1538-7445.am2018-5882
Autor:
Michael Dalton, Michael Baltezor, John A. Taylor, Parthasarathy Ranjarajan, John L. Haslam, Kathy Heppert, Robyn Wood, Lian G. Rajewski, Roy A. Jensen, Amanda E. Brinker, William McCulloch, Shrikant Anant, Scott Weir, Greg Reed, Tammy Ham, Prabhu Ramamoorthy, Michael J. McKenna, Karl Schorno
Publikováno v:
Journal of Clinical Oncology. 36:e14576-e14576
e14576Background: Ciclopirox (CPX) is an antifungal agent contained in a number of FDA-approved topical drug products. CPX possesses anticancer activity in a number of in vitro and in vivo preclini...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d1b7f6361667b896609cc390062329a
https://doi.org/10.1200/jco.2018.36.15_suppl.e14576
https://doi.org/10.1200/jco.2018.36.15_suppl.e14576